Lineage Cell Therapeutics/LCTX

$0.93

-5.1%
-
1D1W1MYTD1YMAX

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Ticker

LCTX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Brian Culley

Employees

75

Headquarters

Carlsbad, United States

LCTX Metrics

BasicAdvanced
$185M
Market cap
-
P/E ratio
-$0.13
EPS
1.30
Beta
-
Dividend rate
$185M
1.29953
$1.61
$0.84
1.1M
2.707
0.109
0.177
-21.32%
-33.12%
-24.82%
23.122
2.555
12.182
-32.48%
3.11%
69.83%

What the Analysts think about LCTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
459.14% upside
High $7.00
Low $4.00
$0.93
Current price
$5.20
Average price target

LCTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-464.28% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.4M
-30%
Net income
-$6.5M
38.3%
Profit margin
-464.28%
97.57%

LCTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.04
-$0.03
-$0.04
-
Expected
-$0.04
-$0.04
-$0.04
-$0.04
-$0.05
Surprise
-32.26%
-6.67%
-30%
4.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Lineage Cell Therapeutics stock?

Lineage Cell Therapeutics (LCTX) has a market cap of $185M as of May 30, 2024.

What is the P/E ratio for Lineage Cell Therapeutics stock?

The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of May 30, 2024.

Does Lineage Cell Therapeutics stock pay dividends?

No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Lineage Cell Therapeutics dividend payment date?

Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Lineage Cell Therapeutics stock price target?

The target price for Lineage Cell Therapeutics (LCTX) stock is $5.2, which is 459.14% above the current price of $0.93. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lineage Cell Therapeutics stock

Buy or sell Lineage Cell Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing